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BACKGROUND: Neuromyelitis Optica spectrum disorder is an 
inflammatory disorder affecting the central nervous system), 
most commonly attacking the spinal cord or optic nerves. 
Limited cases of neuromyelitis optica have been reported in east 
Africa. Based on my review, if published, this would be the 
second published case of Neuromyelitis Optica spectrum 
disorder and the first published case of seropositive 
Neuromyelitis Optica spectrum disorder reported from 
Ethiopia.  It signifies the need to have a high index of suspicion 
to promptly identify and properly treat these patients. 
CASE PRESENTATION: I am reporting a 32 years old female 
patient from Addis Ababa, Ethiopia, who presented with 
recurrent lower limb weakness and impairment of right eye 
vision of two-year duration. She was diagnosed based on 
Neuromyelitis Optica spectrum disorder diagnostic criteria, by 
having transverse myelitis, optic neuritis, confirmed by MRI 
imaging and high level of aquaporin-4-antibodies. Symptoms 
improved after providing five days of Methylprednisolone 
followed by low doses of corticosteroids and Azathioprine. The 
patient is now fully functional except for the right eye vision 
impairment. 
CONCLUSION: The patient described here signifies a classic 
manifestation of Neuromylitis Optica disorder with aquaporin-
4-IgG occurring in Ethiopian woman. This case highlights the 
existence of Devic’s disease within our setting and the need to 
properly diagnose this condition even in a resource-limited 
setting to avert disability. 
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Neuromylitis Optica (NMO) spectrum disorder is an inflammatory 
disorder affecting the central nervous system (CNS), commonly 
attacking the spinal cord or optic nerves (1). It is formerly assumed to 
be closely related to multiple sclerosis but more recently proven to








represent a different clinical and pathophysiologic 
entity (1). This condition is also called Devic’s 
disease or Devic’s syndrome.  NMO spectrum 
disorders include either recurrent longitudinally 
extensive myelitis (more than a three-vertebral 
segment spinal cord lesion seen in MRI) or 
recurrent optic neuritis (2). 
The detection of antibodies to aquaporin-4, (2) a 
water channel found on astrocytic foot processes 
profoundly expressed in the optic nerves, 
brainstem, and spinal cord (1).  It is a highly 
specific biomarker for NMO as well as for NMO 
spectrum disorders and is considered as an 
additional criterion supporting the diagnosis (2).  
The International Panel for Neuromyelitis 
Optica Diagnosis (IPND) updated consensus 
diagnostic criteria incorporating relevant advances 
in 2015 (2).  I am reporting this case considering 
that she fulfills this diagnostic criterion. 
 
Table 1:  International Panel for Neuromyelitis Optica Diagnosis (IPND) updated consensus NMOSD 
diagnostic criteria (2015) for adult patients 
 
IPND updated consensus NMOSD diagnostic criteria(2015) for adult patients 
Diagnostic criteria for NMOSD with AQP4-IgG 
1. At least 1 core clinical characteristic 
2. Positive test for AQP4-IgG using best available detection method (cell-based assay strongly 
recommended) 
3. Exclusion of alternative diagnoses 
 
Diagnostic criteria for NMOSD without AQP4-IgG or NMOSD with unknown AQP4-IgG status 
1. At least 2 core clinical characteristics occurring as a result of one or more clinical attacks and meeting 
all of the following requirements: 
a. At least 1 core clinical characteristic must be optic neuritis, acute myelitis with LETM, or area 
postrema syndrome. 
b. Dissemination in space (2 or more different core clinical characteristics). 
c. Fulfillment of additional MRI requirements, as applicable. 
2. Negative tests for AQP4-IgG using best available detection method, or testing unavailable. 
3. Exclusion of alternative diagnoses. 
Core clinical characteristics 
1. Optic neuritis (Figure 3). 
2. Acute myelitis (Figure 2). 
3. Area postrema syndrome: episode of otherwise unexplained hiccups or nausea and vomiting. 
4. Acute brainstem syndrome. 
5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic 
MRI lesions. 
6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions. 
Additional MRI requirements for NMOSD without AQP4-IgG and NMOSD with unknown 
AQP4-IgG status 
1. Acute optic neuritis: requires brain MRI showing (a) normal findings or only nonspecific white matter 
lesions(Image 1), OR (b) optic nerve MRI with T2-hyperintense lesion or T1-weighted gadolinium 
enhancing lesion extending over >1/2 optic nerve length or involving optic chiasm.  
2. Acute myelitis: requires associated intramedullary MRI lesion extending over >3 contiguous segments 
(LETM) OR >3 contiguous segments of focal spinal cord atrophy in patients with history compatible 
with acute myelitis (Figure 2). 
3. Area postrema syndrome: requires associated dorsal medulla/area postrema lesions. 
4. Acute brainstem syndrome: requires associated periependymal brainstem lesions. 
Abbreviations: AQP4 = Aquaporin-4; IgG = Immunoglobulin G; LETM = Longitudinally Extensive Transverse 
Myelitis Lesions; NMOSD = Neuromyelitis Optica Spectrum Disorders 
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As NMO spectrum disorders carry substantial 
morbidity and, at times, mortality, early and 
accurate diagnosises followed by immediate 
initiation of therapy for both treatments of acute 
exacerbations and prevention of additional relapses 
are critical (1). 
NMO is up to nine times more prevalent in 
women with a median age of onset of 39 years. In 
contrast to Multiple Sclerosis (MS), NMO is 
relatively common in non-whites (3). Limited cases 
of neuromyelitis optica have been reported in East 
Africa (4,5). In Ethiopia two cases have been 
reported, but only one of which was previously 
published (5). 
The low expectation of such diseases in our 
setting, together with diagnostic difficulties, often 
leads to misdiagnosis and poorer outcomes in 
patients that could have benefited from available 
treatment. I believe that the awareness offered here 




History: The patient was a 32 years old female 
from Addis Ababa, Ethiopia. She presented to one 
of the private clinics at Addis Ababa on January 18, 
2017, with weakness on the right lower limb and 
numbness and tingling on the left lower limb of 
three days’ duration.  She had also associated 
urinary urge incontinence with a band like feeling 
on the right trunk below the breast fold. She had 
lost her right eye vision progressively seven 
months before the first visit. On the first visit, she 
was treated with five days of methylprednisolone 
intravenously and followed by oral prednisolone 
for 2 months and showed significant improvement. 
However, after six months of the first visit, the 
patient presented with another attack with 
weakness on the right lower limb of five days’ 
duration with urinary urge incontinence.  She was 
married and a mother of three children. Regarding 
past medical history, she was hypertensive on 
treatment with good control in the last 2 years. 
Otherwise, there was no personal or family history 
of diabetes or cardiac illness.  No history of cough, 
night sweat, weight loss, or skin rash was recorded. 
She had no history of exposure to toxins and travel 
history out of Ethiopia..  
 
Physical examination: On physical examination, 
she was noted to have a visual loss of the right eye 
with pale optic disc but no background change 
noted on fundoscopic examination.  The right eye 
visual acuity was only light perception; left eye 
visual acuity was 6/6. Power on lower limbs was 
3/5(right) and 4/5(left), reflex ¾ both on ankle and 
knee, plantar responses were up going bilaterally. 
Vibration and position sense decreased on the right 
body below the thoracic sixth vertebral spine and 
decreased pain, touch, and temperature sense on the 
left body below the thoracic sixth vertebral spine.  
The rest of the systemic and neurologic 
examination was unremarkable.  
   
Auxiliary examinations: Her complete blood 
count, erythrocyte sedimentation rate, liver 
function test, renal function test, serum 
electrolytes, and plasma glucose levels were 
normal.  Serum VDRL was non-reactive and 
serology for retroviral infections was also negative. 
Serum Antinuclear antibody (ANA) was also 
negative. Serum AQP4-IgG titer (using AQP4-IgG 
serologic assay techniques) was also determined on 
the second attack and reviled 1:200+++ (normal 
value <1:10).  Chest X-ray and abdominopelvic 
ultrasound results were also normal. Her brain MRI 
finding was normal except for the presence of the 
right side atrophied optic nerve (Figure 1). 
Thoracic MRI (Figure 2) revealed hyperintense ill-
defined lesions from the thoracic four (T4) to the 
thoracic seven (T7) spinal cords. However, the 
limitation of this case report was, contrast 
(gadolinium) was not administered during MRI 
study. Visual Evoked Potential (VEP) of the patient 
also revealed left side moderate demyelinating 
optic nerve neurophysiologic impairment (Optic 
neuritis, P100 latency of 128 milliseconds) and 
absent response on the right eye suggesting severe 
optic nerve neurophysiologic impairment (Figure 
3). However, a cerebrospinal fluid analysis was not 
done considering that the case was a patient with 
classic NMOSD. 
 









Figure 1: Magnetic resonance imaging studies. Axial T2-weighted Magnetic resonance imaging of 
the brain showed normal finding except for the presence of right side atrophied optic nerve 
 
Figure 2: Sagittal T2-weighted Magnetic Resonance Imaging demonstrates ill-defined T2 bright signal 
intensities (myelitis) from T4 toT7 (white arrow)  
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Figure 3: Visual evoked potential demonstrates moderately prolonged P100 latency on the left eye and 
absent response on the right eye 
DISCUSSION 
In contrast to Multiple Sclerosis (MS), NMO is 
relatively common in non-whites (3). According to 
my literature review, limited cases of published 
neuromyelitis optica have been reported in east 
Africa. This case shows the existence of NMO 
spectrum disorder with aquaporin-4-IgG occurring 
in Ethiopian patients.   
My patient meets the International Panel for 
Neuromyelitis Optica Diagnosis (IPND) consensus 
diagnostic criteria 2015 (Table 1) (2).  These 
criteria allow NMOSD diagnosis with the presence 
of at least 1 of 6 core clinical characteristics and 
detection of AQP4-IgG (2). Diagnostic necessities 
are strict for patients in whom AQP4-IgG is not 
detected or for whom testing is unavailable. Such 
individuals must experience 2 or more different 
core clinical characteristics (i.e., dissemination in 
space, affecting different neuroanatomic regions) 
and other supportive MRI features meant to enrich 
diagnostic specificity must also be present. The two 
required core characteristics may occur with a 
single clinical attack (e.g., classic Devic syndrome 
with simultaneous optic neuritis and acute myelitis 
with LETM) or multiple attacks (2). Meeting this 
criterion in my setting may still be challenging, 
particularly since serologic assays are not readily 
available, even if its absence does not prohibit the 
diagnosis and providing correct treatment. The 
previously reported case in Ethiopia was also based 
on clinical criteria where serum level of AQP4-IgG 
level was not determined. This makes my case the 
first NMOSD patient with serologic evidence of 
AQP4-IgG if published. 
Patients with attacks of NMOSD develop 
significant disability if untreated (1). This is in 
contrast with individuals with multiple sclerosis 
who usually have relatively better recovery from 
attacks but develop a disability in the later, 
progressive stages of the disease (1). This is 
evidenced in this patient that she lost her right eye 
vision since she did not get timely intervention, but 
she had significant improvement and no disability 
on the subsequent extensive attacks (myelitis) 
because of early interventions (administration of 








immunotherapy). Therefore, a high index of 
suspicion is essential to make this diagnosis early 
and demonstrate the need for timely and prompt 
diagnosis to delay unfavorable consequences. This 
case is a leaving experience that emphasizes the 
importance of early intervention.  
The patient described here signifies a classic 
manifestation of NMO spectrum disorder with 
aquaporin- 4-IgG occurring in this Ethiopian 
woman. The low expectation of such diseases in 
my setting, together with diagnostic difficulties, 
often leads to misdiagnosis and poorer outcomes. 
This case highlights the existence of Devic’s 
disease within our setting and the need to properly 
diagnose this condition even in a resource-limited 
setting to avert disability by intervening timely. I 
believe that the awareness offered here may be 









1. Ilana Katz Sand. A review article on 
Neuromyelitis Optica Spectrum Disorders. 
Continuum (Minneap Minn) 2016; 22(3):864–
896. 
2. Wingerchuk DM, Banwell B, Bennett JL, et al. 
International consensus diagnostic criteria for 
neuromyelitis optica spectrum disorders. 
Neurology 2015;85(2):177Y189. 
DOI:10.1212/WNL.0000000000001729.  
3. Wingerchuk DM, Lennon VA, Lucchinetti CF, 
Pittock SJ, Weinshenker BG. The spectrum of 
neuromyelitis optica. Lancet Neurol. 2007; 
6(9):805-15.    
4. Kaddumukasa M, Musubire A, K addumukasa 
M, Matovu S, Katabira E. Case report: 
Neuromyelitis optica in a Ugandan woman. 
Journal of medical case reports 2013, 7:177.  
5. Abdulaziz Jemal, Abate Bane, Seid Ali. Case 
report: 24-year-old female with neuromyelitis 
optica from Ethiopia. Ethiop Med J, 2017, Vol 
55, No.4. 
 
 
